Servier hit by bone drug safety issues as Mediator continues to make waves
This article was originally published in Scrip
The French company Servier, already staggering under the weight of the Mediator affair, is again under fire, this time over the safety profile of its osteoporosis drug, Protelos (strontium ranelate). A French committee is examining the pharmacovigilance data on the product to see whether its risk-benefit profile needs to change, and Servier's pharmacovigilance systems are also under the spotlight.
You may also be interested in...
Panelists at a recent virtual session of the DIA’s Europe 2020 conference identified the positive and negative aspects of Europe’s response to the pandemic, and suggested ways of avoiding shortages and making the supply chain more resilient in the event of future crises.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.